Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Page 1 de 20 résultats
Silymarin in COVID-19 Pneumonia
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
To date, there are no drugs or other therapeutics approved by the U.S. Food and Drug Administration (FDA) to prevent or treat COVID-19 that has spread globally resulting in the ongoing pandemic as declared by the World Health Organization (WHO) on 11 March 2020. While the majority of patients have
The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Beta-Thalassemia is a major public health problem in Mediterranean countries , parts of North and West Africa, the Middle East, the Indian subcontinent, southern Far East and southeastern Asia is of the highest incidence. In Egypt, it is considered as the most common chronic hemolytic anemia (85.1%)
Silymarin in NAFLD
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
In this study will participate patients who come to the regular ambulatory examinations (referred by gastroenterologists, nephrologists or family physicians in the Department of Gastroenterology and Department of Nephrology, dialysis and kidney transplantation KBC Rijeka) and have one or more
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
A correct hepatic function is highly relevant from the epidemiological point of view. In Italy, Non Alcoholic Fatty Liver Disease - NAFLD - has a prevalence of 20-25% in the adult population, with peaks of 50-70% within obese and type-2 diabetes populations: it is the most frequent cause of hematic
Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
OBJECTIVES OF STUDY Primary Objectives
1. To assess the safety and adverse event profile of Silymarin compared to placebo.
2. To assess the efficacy of Silymarin as defined by an improvement in non-alcoholic steatosis (NAS) activity score by at least 30% from baseline compared to placebo.
Secondary
THISTLE - The HIV-HCV Silibinin Trial
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
- Prevention of antituberculosis-related drug induced liver injury with silymarin is investigated.
Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Hepatitis C virus (HCV)-related liver disease continues to be the most common indication for liver transplantation (LT) in both the United States and Europe. However, LT does not cure the infection, and re-infection of the liver allograft universally occurs. Recurrent HCV hepatitis often follows an
Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
To Study the Efficacy and Safety of Renessans in Chronic HCV Patients
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
1. Primary
The primary objective of this study is to assess the efficacy of combination therapy comprising of RENESSANS, INTERFERONS and RIBAVIRIN in the management of treatment naïve HCV related Chronic Active Hepatitis patients.
2. Secondary
The secondary objectives of this study are:
1. Determine
Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Silymarin has been claimed to have a beneficial effect in various types of liver injury, including alcoholic liver disease, drug and toxin induced hepatotoxicity, and acute and chronic viral hepatitis.
Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Silymarin and green tea are the two most widely used botanical products used by patients with chronic hepatitis C virus (HCV) infection. A major limitation of prior clinical investigations that may account for lack of efficacy is their use of inadequate customary oral dose regimens. Ongoing Phase II
Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
Currently, acute viral hepatitis (AVH) management is based on diet and rest and silymarin remains among the most popular herbs being used for treating viral hepatitis both in the U.S. and abroad. Although numerous randomized clinical trials have been conducted to assess the efficacy of silymarin on
Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
This proposal is a phase II study that will evaluate the safety and efficacy of silymarin for the treatment of subjects with chronic hepatitis C who did not respond to conventional antiviral therapy. The primary objectives of this study are to assess the safety and adverse event profile of silymarin
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
